araag2/HINT huggingface dataset:
Clinical trial NCT00003235 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed unresectable stage IIIA or IIIB non-small
        cell carcinoma of the lung Adenocarcinoma Squamous cell carcinoma Anaplastic large cell
        carcinoma Stage IIIA patients must not be candidates for resection after neoadjuvant
        therapy (unresectable T3N1 or T1-3 primary tumors with metastasis limited to the
        ipsilateral mediastinal and subcarinal lymph nodes) Mediastinotomy or thoracoscopy required
        for potentially resectable IIIa disease when ipsilateral mediastinal lymph nodes are less
        than 2 cm Stage IIIB patients must not have significant pleural effusion (seen on CT scan
        only OR does not reaccumulate after one thoracentesis and is cytologically negative)
        Metastases to contralateral mediastinal or supraclavicular nodes allowed Measurable or
        evaluable disease No distant metastasis or significant pleural effusion

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At
        least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3
        Granulocyte count at least 1,500/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less
        than 1.5 mg/dL SGOT no greater than 2 times normal No liver disease with significant
        hepatic insufficiency Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance
        at least 50 mL/min Cardiovascular: No cardiac arrhythmia or end stage congestive heart
        failure Neurologic: No preexisting clinically significant peripheral neuropathy No organic
        brain syndrome Other: No history of prior or concurrent malignancy in the past 5 years
        except: Surgically cured basal cell carcinoma of the skin Carcinoma in situ of the cervix
        Not pregnant Fertile patients must use effective contraception during and for 2 weeks after
        study

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic radiotherapy
        Surgery: Not specified
Clinical trial NCT00256750 (phase 3, status: completed)
Conditions: kidney transplantation, chronic kidney failure
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, N99.0, I13.0, I13.10, I13.11, I13.2
Drugs: cyclosporine (csa), belatacept li (less intensive), belatacept mi (more intensive)
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  The subject is a recipient of a living donor or deceased donor kidney transplant.

          -  Male or Female, 18 or older

        Exclusion Criteria:

          -  First time recipient, PRA >- 50% or for retransplantation PRA >- 30%.

          -  If retransplantation, previous graft loss cannot be due to acute rejection.

          -  Positive cross match.

          -  Subject receiving extended criteria donor (ECD) organ

          -  For Long-term extension study-Subjects who have completed three years of study
             treatment (through Week 156)
Clinical trial NCT01359956 (phase 3, status: completed)
Conditions: malignant melanoma, recurrent melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: dacarbazine, fotemustine, interferon alfa-2b
SMILES: N1C=CN=C1, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O, O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of malignant melanoma in advanced stage or
             recurrent after surgery, and not amenable to further surgery or local therapy.

          -  Presence of measurable disease

          -  Age > or = 18 years and < or = 75 years

          -  Performance status (ECOG) 0 - 2 (Appendix 2)

          -  Life expectancy ³ 3 months

          -  Adequate bone marrow function (ANC ³ 2,000/mmc; PTL ³ 100,000/mmc; Hb ³ 10 gr/dl),
             normal liver and renal function (bilirubin < 1.25 x N, creatinine < 1.25 x N, SGOT,
             SGPT < 3 times upper normal limit of testing laboratory.

          -  Written, informed consent prior to study specific procedures, with the understanding
             that the patient has the right to withdraw from the study at any time, without
             prejudice.

          -  Prior surgery > 3 weeks from initiating .

          -  If palliative radiation is needed, in case of non target lesions, it must be given
             prior to initiating chemotherapy. If palliative radiation is required during the study
             the patient should be permanently discontinued from further treatment.

          -  Adequate contraceptive measures during study participation for sexually active
             patients of child bearing potential must implement.

        Exclusion Criteria:

          -  Previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the
             skin.

          -  Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed)

          -  Known HIV disease.

          -  Concurrent treatment with other experimental drugs.

          -  Concurrent chemotherapy, immunotherapy, hormonal therapy (excluding contraceptives and
             replacement steroids), radiation therapy

          -  Pregnant or lactating females Previous or concurrent malignancies at other sites with
             the exception of surgically cured carcinoma in-site of the cervix and basal or
             squamous cell carcinoma of the skin.

        Prior chemo-immunotherapy ( previous adjuvant immunotherapy is allowed) Known HIV disease.
        Concurrent treatment with other experimental drugs. Concurrent chemotherapy, immunotherapy,
        hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy
Clinical trial NCT00673049 (phase 3, status: terminated)
Conditions: carcinoma, large cell, carcinoma, non-small-cell lung, carcinoma, squamous cell, carcinoma, adenosquamous cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, D02.20, D02.21, D02.22, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cp 751,871 (figitumumab), erlotinib, erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Non small cell lung cancer with a primary histology of squamous cell, large cell or
             adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

        Exclusion Criteria:

          -  Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.

          -  Prior Erlotinib therapy.

          -  Prior anti IGF IR based investigational therapy.
Clinical trial NCT00094458 (phase 3, status: completed)
Conditions: crohn disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: infliximab (ifx) placebo infusion; azathioprine (aza) caps
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Crohns Disease for at least 6 weeks

          -  Moderate to severe disease activity (CDAI >= 220 and <=450)

          -  No history of azathioprine, 6-MP (6 Mercaptopurine), or biologic treatments

          -  Are either: Corticosteriod-dependent, OR considered for a 2nd (or greater) course of
             corticosteriod, OR 5-ASA failures, Or Budesonide failures

        Exclusion Criteria:

          -  History of abdominal surgery within the last 6 months

          -  Have an ostomy or stoma [An operation to create an opening from an area inside the
             body to the outside]

          -  Are pregnant, nursing, or planning pregnancy (both men and women)

          -  Serious simultaneous illness that could interfere with study participation

          -  Use of any investigational drug within 30 days

          -  Have a concomitant diagnosis or any history of congestive heart failure

          -  Weigh more than 140 kilograms (or 310 pounds)
Clinical trial NCT01159912 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone propionate, fluticasone furoate, placebo
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Outpatient at least 12 years of age

          -  Both genders; females of child bearing potential must be willing to use approved birth
             control method

          -  Pre-bronchodilator FEV1 of 40-90% predicted

          -  Reversibility FEV1 of at least 12% and 200mLs

          -  Current asthma therapy that includes an inhaled corticosteroid for at least 4 weeks
             prior to first visit

        Exclusion Criteria:

          -  History of life threatening asthma

          -  Respiratory infection or candidiasis

          -  Asthma exacerbation within 6 months prior to first visit

          -  Concurrent respiratory disease or other disease that would confound study
             participation or affect subject safety

          -  Allergies to study drugs, study drug excipients, medications related to study drugs

          -  Taking another investigational medication or medication prohibited for use during this
             study
Clinical trial NCT00697073 (phase 3, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: idebenone
SMILES: COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Friedreich's ataxia patients completing core study SNT-III-002 (NCT00537680) and
             presenting at Week 24 (Visit 5) of that study

          -  Body weight ≥ 25kg/55 lbs

          -  Negative urine pregnancy test

          -  Patients who in the opinion of the investigator are able to comply with the
             requirements of this study

        Exclusion criteria:

          -  Adverse events during the course of SNT-III-002(NCT00537680)which in the opinion of
             the investigator are attributable to idebenone and preclude further treatment with
             idebenone

          -  Clinically significant abnormalities of clinical hematology or biochemistry including,
             but not limited to, elevations greater than 2 times the upper limit of normal of AST,
             ALT or creatinine

          -  Treatment with coenzyme Q10, vitamin E (if taken at a dose 5 times above the daily
             requirement) or other sources of idebenone within the past month

          -  Parallel participation in another clinical drug trial

          -  Past or present history of abuse of drugs or alcohol

          -  Pregnancy or breast-feeding
Clinical trial NCT00358917 (phase 3, status: completed)
Conditions: human immunodeficiency virus infections
ICD codes: Z21
Drugs: lopinavir/ritonavir (lpv/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (nrtis), lopinavir/ritonavir (lpv/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (nrtis)
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects were human immunodeficiency virus type 1 (HIV-1) positive,
             antiretroviral-experienced adults at least 18 years of age currently receiving an
             antiretroviral regimen which had not changed for at least 12 weeks.

          -  Subjects had plasma HIV-1 ribonucleic acid (RNA) levels > 1,000 copies/mL at screening
             and were not acutely ill.

          -  Subject was currently failing his/her antiretroviral regimen with the most recent 2
             consecutive prestudy plasma HIV-1 RNA levels > 400 copies/mL with the most recent
             being > 1000 copies/mL, and in the investigator's opinion, should change therapy

          -  Female subjects were nonpregnant and nonlactating.

        Exclusion Criteria:

          -  Subjects were excluded if screening laboratory analyses showed hemoglobin <= 8.0 grams
             per deciliter.

          -  Subjects were excluded if screening laboratory analyses showed absolute neutrophil
             count <= 750 cells/microliter.

          -  Subjects were excluded if screening laboratory analyses showed platelet count <=
             50,000 per cubic millimeter.

          -  Subjects were excluded if screening laboratory analyses showed alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) >= 5.0 x upper limit of
             normal (ULN).
Clinical trial NCT00144521 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: mra(tocilizumab), mra placebo, mtx, mtx placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria

          -  Diagnosis of RA based on the 1987 classification criteria of the American College of
             Rheumatology (ACR)

          -  Disease duration of 6 months or more

          -  Treated with 8 mg/week of MTX for at least 8 weeks immediately preceding enrollment,
             and continued on this treatment up to initiation of the study drug

          -  Active disease at enrollment (less than 2 weeks before initiating treatment with a
             study drug), Which is defined as having at least 6 tender and 6 swollen joints among
             49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation
             Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL

        Exclusion criteria

          -  Assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding
             treatment with the study drug

          -  Treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment
             with the study drug

          -  Received any of the following therapies in the 2 weeks preceding initiation of
             treatment with the study drug.

               1. Administration of any DMARD or immunosuppressant other than MTX

               2. Administration of corticosteroids exceeding 10 mg/day as prednisolone

               3. Dose escalation or initiation of corticosteroids

          -  Received any of the following therapies in the 4 weeks preceding treatment with the
             study drug

               1. Plasma exchange therapy

               2. Surgical treatment (operation, etc.)
Clinical trial NCT00275106 (phase 3, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisolone, thioguanine, vincristine sulfate
SMILES: N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, NC1=NC(=S)C2=C(N1)N=CN2, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    withdrawn due to an excess of toxic deaths
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed lymphoblastic lymphoma (LBL)

               -  Stage I-IV disease

               -  T-cell LBL, precursor B-cell LBL, or LBL with an unknown immunophenotype

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No known HIV or AIDS infection

          -  No severe immunodeficiency

          -  No other prior malignancy

          -  No prior disease that would preclude treatment with chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  More than 2 months since prior systemic corticosteroids for a duration of > 8 days

          -  No prior chemotherapy

          -  No prior radiotherapy

          -  No prior organ transplant

          -  No trimethoprim-sulfamethoxazole 6 days before or during methotrexate therapy

          -  No concurrent participation in another clinical trial
Clinical trial NCT01184664 (phase 3, status: completed)
Conditions: tobacco dependence, smoking cessation
ICD codes: F17.220, F17.221, F17.223, F17.290, F17.291, F17.293, Z81.2, Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine patch, placebo, varenicline
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21
Eligibility criteria:

        Inclusion Criteria:

          -  Smokers seeking treatment

          -  Aged 18 and over

          -  Consenting to take part in the trial

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  End-stage renal disease

          -  Unable to fill in questionnaires in English

          -  Previous allergy to Varenicline

          -  Previous allergy to Nicotine Patches Previous allergy to varenicline
Clinical trial NCT01263015 (phase 3, status: completed)
Conditions: infection, human immunodeficiency virus i
ICD codes: Z21
Drugs: dolutegravir, atripla, abacavir/lamivudine, abacavir/lamivudine placebo, dolutegravir placebo, atripla placebo
SMILES: N[C@@H](CO)C(O)=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, N[C@@H](CO)C(O)=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Screening plasma HIV-1 RNA ≥1000 c/mL

          -  Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent
             following a diagnosis of HIV-1 infection)

          -  Ability to understand and sign a written informed consent form

          -  Willingness to use approved methods of contraception to avoid pregnancy (women of
             child bearing potential only)

          -  Age equal to or greater than 18 years

          -  A negative HLAB*5701 allele assessment

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding;

          -  Active Center for Disease and Prevention Control (CDC) Category C disease

          -  Hepatic impairment

          -  HBV co-infection

          -  Anticipated need for HCV therapy during the study

          -  Allergy or intolerance to the study drugs or their components or drugs of their class

          -  Malignancy within the past 5 years

          -  Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

          -  Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any
             immunomodulator within 28 days of Screening

          -  Exposure to an agent with documented activity against HIV-1 in vitro or an
             experimental vaccine or drug within 28 days of first dose of study medication

          -  Primary viral resistance in the Screening result

          -  Verified Grade 4 laboratory abnormality

          -  ALT >5 xULN

          -  ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with >35% direct bilirubin);

          -  Estimated creatinine clearance <50 mL/min

          -  Recent history (≤3 months) of upper or lower gastrointestinal bleed
Clinical trial NCT00312806 (phase 3, status: completed)
Conditions: gastroesophageal reflux disease (gerd)
ICD codes: K22.6, K21.9, K21.00, K21.01
Drugs: pantoprazole
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Written informed consent

          -  Outpatients of at least 18 years (21 years in Argentina)

          -  Patient considered to have GERD symptoms

        Main Exclusion Criteria:

          -  Acute peptic ulcer and/or ulcer complications

          -  Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including
             COX-2-inhibitors (> 5 days on demand but not more than 3 consecutive days) during the
             last 28 days before study start (except regular intake of acetylsalicylic acid at a
             dose up to 163 mg/day)

          -  Intake of proton pump inhibitors during the last 10 days before study start

          -  Female patients of childbearing potential not using adequate means of birth control

          -  Pregnant or breast-feeding females